Protection from gentamicin ototoxicity by iron chelators in guinea pig in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 1, 1997, Pages 369-377

  Song, Ben Bo ^a   Anderson, David J ^a   Schacht, Jochen ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDROXYBENZOIC ACID; CHELATING AGENT; DEFEROXAMINE; FREE RADICAL; GENTAMICIN; MANNITOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; AUDITORY THRESHOLD; CONTROLLED STUDY; EAR PROTECTION; ESCHERICHIA COLI; GUINEA PIG; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; ANTI-BACTERIAL AGENTS; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; GENTAMICINS; GUINEA PIGS; HEARING DISORDERS; IRON; IRON CHELATING AGENTS; MALE; NYSTAGMUS, OPTOKINETIC; SERUM ALBUMIN; WEIGHT GAIN;

EID: 0030778977     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. ALI, B. H.: Gentamicin nephrotoxicity in humans and animals: some recent research. Gen. Pharmacol. 26: 1477-1487, 1995.
2. BEGG, E. J. AND BARCLAY, M. L.: Aminoglycosides-50 years on. Br. J. Clin. Pharmacol. 39: 597-603, 1995.
3. BEN ISMAIL, T. H., ALI, B. H. AND BASHIR, A. A.: Influence of iron, deferoxamine and ascorbic acid on gentamicin-induced nephrotoxicity in rats. Gen. Pharmacol. 25: 1249-1252, 1994.
4. BENTUR, Y., KOREN, G., TESORO, A., CARLEY, H., OLIVIERI, N. AND FREEDMAN, M. H.: Comparison of deferoxamine pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe neurotoxicity. Clin. Pharmacol. Ther. 47: 478-482, 1990.
5. BOCK, G. R., YATES, G. K., MILLER, J. J. AND MOORJANI, P.: Effects of N-acetylcysteine on kanamycin ototoxicity in the guinea pig. Hear. Res. 9: 255-262, 1983.
6. CHAPIN-ROBERTSON, K. AND EDBERG, S. C.: Measurement of antibiotics in human body fluids: Techniques and significance. In Laboratory Medicine, 3rd ed., ed. by V. Lorain, pp. 295-304, Williams & Wilkins, Baltimore, 1991.
7. CLARKE, N. E., CLARKE, C. N. AND MOSHER, R. E.: Phenolic compounds in chemotherapy of rheumatic fever. Am. J. Med. Sci. 235: 7-22, 1958.
8. COHEN, A., MARTIN, M., MIZANIN, J., KONKLE, D. F. AND SCHWARTZ, E.: Vision and hearing during deferoxamine therapy. J. Pediatr. 117: 326-330, 1990.
9. CRANN, S. A., HUANG, M. Y., MCLAREN, J. D. AND SCHACHT, J.: Formation of a toxic metabolite from gentamicin by a hepatic cytosolic fraction. Biochem. Pharmacol. 43: 1835-1839, 1992.
10. CRANN, S. A. AND SCHACHT, J.: Activation of aminoglycoside antibiotics to cytotoxins. Audiol. Neuro-Otol. 1: 80-85, 1996.
11. DURAK, J., KAVUTCU, M., CANBOLAT, O., OZTURK, S., ULUTEPE, S. AND GOKHUN, I. H.: Effects of gentamicin on iron and copper contents of kidney tissue. Nephron 70: 380-381, 1995.
12. GALLANT, T., BOYDEN, M. H., GALLANT, L. A., CARLEY, H. AND FREEDMAN, M. H.: Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy. Am. J. Med. 83: 1085-1090, 1987.
13. GARETZ, S. L., ALTSCHULER, R. A. AND SCHACHT, J.: Attenuation of gentamicin ototoxicity by glutathione in the guinea pig in vivo. Hear. Res. 77: 81-87, 1994a.
14. GARETZ, S. L., RHEE, D. J. AND SCHACHT, J.: Sulfhydryl compounds and antioxidants inhibit cytotoxicity to outer hair cells of a gentamicin metabolite in vitro. Hear. Res. 77: 75-80, 1994b.
15. GARETZ, S. L. AND SCHACHT, J.: Ototoxicity: Of mice and men. In Handbook of Auditory Research, ed. by R. R. Fay and A. N. Popper, Vol. VII: Clinical Aspects of Hearing, ed. by T. R. Van De Water, A. N. Popper, and R. R. Fay, pp. 116-154, Springer, New York, 1996.
16. GRAZIANO, J. H.: Iron metabolism and chelation therapy in hemosiderosis. Curr. Topics Hematol. 1: 127-150, 1978.
17. GRAZIANO, J. H., MARKENSON, A., MILLER, D. R., CHANG, H., BESTAK, M., MEYERS, P., PISCIOTTO, P. AND RIFKIND, A.: Chelation therapy in β-thalassemia major: I. Intravenous and subcutaneous desferrioxamine. J. Pediatr. 92: 648-652, 1978.
18. GUTTERIDGE, J. M. C., RICHMOND, R. AND HALLIWELL, B.: Inhibition of the iron-catalysed formation of hydroxyl radiais from Superoxide and of lipid peroxidation of desferrioxamine. Biochem. J. 184: 469-472, 1979.
19. HERSHKO, C.: Iron chelators in medicine. Molec. Asp. Med. 13: 113-165, 1992.
20. HUANG, M. Y. AND SCHACHT, J.: Formation of a cytotoxic metabolite from gentamicin by liver. Biochem. Pharmacol. 40: R11-R14, 1990.
21. KANNO, H., YAMANOBE, S. AND RYBAK, L. P.: The ototoxicity of deferoxamine mesylate. Am. J. Otolaryngol. 16: 148-152, 1995.
22. KAYS, S. E., CROWELL, W. A. AND JOHNSON, M. A.: Iron supplementation increases gentamicin nephrotoxicity in rats. J. Nutr. 121: 1869-1875, 1991.
23. LAUTERMANN, J., MCLAREN, J. AND SCHACHT, J.: Glutathione protection against gentamicin ototoxicity depends on nutritional status. Hear. Res. 86: 15-24, 1995.
24. MARTINI, E. AND PONZIO, E.: Pharmacology of 2,3-dihydroxybenzoic acid. Arch. Ital. Sci. Farmacol. 2: 259-260, 1952.
25. PEARCE, R. A., FINLEY, R. J., MUSTARD, R. A. AND DUFF, J. H.: 2,3-Dihydroxybenzoic acid: Effect on mortality rate in a septic rat model. Arch. Surg. 120: 937-940, 1985.
26. PETERSON, C. M., GRAZIANO, J. H., GRADY, R. W., JONES, R. L., MARKENSON, A., LAVI, U., CANALE, V. C., GRAY, G. F., CERAMI, A. AND MILLER, D. R.: Chelation therapy in β-thalassemia major: A one-year double blind study of 2,3-dihydroxybenzoic acid. Exp. Hematol. 7: 74-80, 1979.
27. PIERSON, M. G. AND MØLLER, A. R.: Prophylaxis of kanamycin-induced ototoxicity by a radioprotectant. Hear. Res. 4: 79-87, 1981.
28. PRIUSKA, E. M. AND SCHACHT, J.: Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex. Biochem. Pharmacol. 50: 1749-1752, 1995.
29. RAPHAEL, Y. AND ALTSCHULER, R. A.: Scar formation after drug-induced cochlear insult. Hear. Res. 51: 173-184, 1991.
30. RUUTU, R.: Determination of iron and unsaturated iron-binding capacity in serum with ferrozine. Clin. Chim. Acta 61: 229-232, 1975.
31. SCHACHT, J.: Biochemical basis of aminoglycoside ototoxicity. Otolaryngol. Clin. North Am. 26: 845-856, 1993.
32. SHA, S.-H. AND SCHACHT, J.: Amplification of free radicals by gentamicin in a biological system (Abstract). Abs. Assoc. Res. Otolaryngol. 19: 30, 1996.
33. SHIRANE, M. AND HARRISON, R. V.: The effects of deferoxamine mesylate and hypoxia on the cochlea. Acta Otolaryngol. (Stockh.) 16: 334-339, 1987.
34. SONG, B.-B. AND SCHACHT, J.: Variable efficacy of radical scavengers and iron chelators to attenuate gentamicin ototoxicity in guinea pig in vivo. Hear. Res. 94: 87-93, 1996.
35. STARKE, P. E. AND FARBER, J. L.: Ferric iron and Superoxide ions are required for the killing of cultured hepatocytes by hydrogen peroxide: Evidence for the participation of hydroxyl radicals formed by an iron-catalyzed Haber-Weiss reaction. J. Biol. Chem. 260: 10099-10104, 1985.
36. STRATTA, P., SEGOLONI, G. P., CANAVESE, C., MUZIO, G., DOGLIANI, M., SERRA, A., ALLEMANDI, P., SALOMONE, M., CARAMELLINO, C. AND CANUTO, R.: Oxygen free radicals are not the main factor in experimental gentamicin nephrotoxicity. Ren. Fail. 16: 445-455, 1994.
37. VAN ASBECK, B. S., MARCELIS, J. H., VAN KATS, J. H., JAARSMA, E. Y. AND VERHOEF, J.: Synergy between the iron chelator deferoxamine and the antimicrobial agents gentamicin, chloramphenicol, cefalothin, cefotiam and cefsulodin. Eur. J. Clin. Microbiol. 2: 432-438, 1983.
38. VOEST, E. E., VREUGDENHIL, G. AND MARX, J. J.: Iron-chelating agents in non-iron overload conditions. Ann. Intern. Med. 120: 490-499, 1994.
39. WALKER, P. D. AND SHAH, S. V.: Evidence suggesting a role for hydroxyl radical in gentamicin-induced acute renal failure in rats. J. Clin. Invest. 81: 334-341, 1988.
40. WANG, H., PRIUSKA, E. M. AND SCHACHT, J.: The iron embrace: exposing the secret activities of gentamicin (Abstract). Abs. Assoc. Res. Otolaryngol. 19: 29, 1996.